Skip to main content

Table 1 Clinical characteristics in the four subtypes

From: Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors

Variable

All tumors

TC

AC

LCNEC

SCLC

NA

159 (100.0)

35 (100.0)

2 (100.0)

28 (100.0)

94 (100.0)

Age

 < =59.5

78 (49.1)

25 (71.4)

2 (100.0)

12 (42.9)

39 (41.5)

 

 > 59.5

81 (50.9)

10 (28.6)

0 (0.0)

16 (57.1)

55 (58.5)

 

Gender

 Male

109 (68.6)

17 (48.6)

0 (0.0)

23 (82.1)

69 (73.4)

 

 Female

50 (31.4)

18 (51.4)

2 (100.0)

5 (17.9)

25 (27.6)

 

Necrosis

 No

85 (53.5)

35 (100.0)

0 (0.0)

9 (32.1)

41 (43.6)

 

 Yes

74 (46.5)

0 (0.0)

2 (100.0)

19 (67.9)

53 (56.4)

 

Vascular invasion

 No

129 (81.1)

34 (97.1)

1 (50.0)

22 (78.6)

72 (76.6)

 

 Yes

30 (18.9)

1 (2.9)

1 (50.0)

6 (21.4)

22 (23.4)

 

Preoperative therapy

 No

150 (94.3)

35 (100.0)

2 (100.0)

27 (96.4)

86 (91.5)

 

 Yes

9 (5.7)

0 (0.0)

0 (0.0)

1 (3.6)

8 (8.5)

 

First location

 Lung

131 (82.4)

35 (100.0)

2 (100.0)

28 (100.0)

66 (70.2)

 

 Lymph Node

28 (17.6)

0 (0.0)

0 (0.0)

0 (0.0)

28 (29.8)

 

Lymph Node Metastasis

     

13 (8.2)

 No

83 (52.2)

32 (97.0)

1 (50.0)

14 (60.9)

36 (40.9)

 

 Yes

63 (47.8)

1 (3.0)

1 (50.0)

9 (39.1)

52 (59.1)

 

Clinical Staging

     

15 (9.4)

 I

70 (48.6)

30 (90.9)

1 (50.0)

10 (43.5)

29 (33.7)

 

 II

27 (18.8)

2 (6.1)

0 (0.0)

9 (39.1)

16 (18.6)

 

 III

47 (32.6)

1 (3.0)

1 (50.0)

4 (17.4)

41 (47.7)

 

Patterns of PD-L1

 Tumorpos stromaneg

9 (5.7)

3 (8.6)

0 (0.0)

5 (17.8)

1 (1.1)

 

 Stromapostumorneg

46 (28.9)

0 (0.0)

0 (0.0)

12 (42.9)

34 (36.2)

 

 Tumor and stromapos

17 (10.7)

0 (0.0)

0 (0.0)

4 (14.3)

13 (13.8)

 

 Tumor and stromaneg

87 (54.7)

32 (91.4)

2 (100.0)

7 (25.0)

46 (48.9)

 

CD8 density/mm2 in stroma

  ≤ 264.6/mm2

80 (50.3)

23 (65.7)

0 (0.0)

7 (25.0)

50 (53.2)

 

  > 264.6/mm2

79 (49.7)

12 (34.3)

2 (100.0)

21 (75.0)

44 (46.8)

 
  1. Abbreviation: NA not available